One-Shot gene therapy aims to halt blinding eye disease
NCT ID NCT06765980
Summary
This is an early-stage study testing a new, one-time gene therapy injection for people with geographic atrophy, a severe form of age-related macular degeneration that causes permanent vision loss. Researchers will give the therapy to about 62 adults to see if it is safe and if it can slow the growth of the damaging lesions in the eye. The main goal is to find a safe dose and see if the treatment can help control the disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kriya Clinical Study Site
RECRUITINGOttawa, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kriya Clinical Study Site
RECRUITINGChristchurch, New Zealand
Conditions
Explore the condition pages connected to this study.